Last reviewed · How we verify
Aplisol@ PPD material
Aplisol is a purified protein derivative (PPD) used as a skin test to diagnose tuberculosis infection.
Aplisol is a purified protein derivative (PPD) used as a skin test to diagnose tuberculosis infection. Used for Diagnosis of tuberculosis infection.
At a glance
| Generic name | Aplisol@ PPD material |
|---|---|
| Also known as | Aplisol@ |
| Sponsor | JHP Pharmaceuticals LLC |
| Drug class | Purified protein derivative |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
Aplisol works by inducing a localized immune response in the skin, which is then evaluated for signs of infection. This allows healthcare professionals to determine if a person has been infected with Mycobacterium tuberculosis. The reaction to the PPD test is a result of the body's immune response to the presence of the bacteria.
Approved indications
- Diagnosis of tuberculosis infection
Common side effects
- Redness, swelling, or itching at the injection site
Key clinical trials
- Equivalence Study of Tuberculin Purified Protein Derivative in Comparison With a Reference Standard (PPD-S2) (PHASE2)
- Equivalence Study of Specificity of PPD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aplisol@ PPD material CI brief — competitive landscape report
- Aplisol@ PPD material updates RSS · CI watch RSS
- JHP Pharmaceuticals LLC portfolio CI